JP2018522880A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522880A5
JP2018522880A5 JP2017568234A JP2017568234A JP2018522880A5 JP 2018522880 A5 JP2018522880 A5 JP 2018522880A5 JP 2017568234 A JP2017568234 A JP 2017568234A JP 2017568234 A JP2017568234 A JP 2017568234A JP 2018522880 A5 JP2018522880 A5 JP 2018522880A5
Authority
JP
Japan
Prior art keywords
cancer
dengue virus
denv
composition according
pfu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017568234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522880A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/040787 external-priority patent/WO2017004567A1/en
Publication of JP2018522880A publication Critical patent/JP2018522880A/ja
Publication of JP2018522880A5 publication Critical patent/JP2018522880A5/ja
Priority to JP2021113634A priority Critical patent/JP2021176862A/ja
Pending legal-status Critical Current

Links

JP2017568234A 2015-07-02 2016-07-01 デングウイルス及び樹状細胞による併用療法のための組成物及び方法 Pending JP2018522880A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021113634A JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562231351P 2015-07-02 2015-07-02
US62/231,351 2015-07-02
PCT/US2016/040787 WO2017004567A1 (en) 2015-07-02 2016-07-01 Compositions and methods for combination therapy with dengue virus and dendritic cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021113634A Division JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2018522880A JP2018522880A (ja) 2018-08-16
JP2018522880A5 true JP2018522880A5 (enExample) 2019-08-08

Family

ID=57609586

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017568234A Pending JP2018522880A (ja) 2015-07-02 2016-07-01 デングウイルス及び樹状細胞による併用療法のための組成物及び方法
JP2021113634A Pending JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021113634A Pending JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Country Status (8)

Country Link
US (6) US9730989B2 (enExample)
EP (1) EP3316897A4 (enExample)
JP (2) JP2018522880A (enExample)
CN (1) CN107921063A (enExample)
CA (1) CA2991212A1 (enExample)
DE (1) DE202016008300U1 (enExample)
MX (1) MX2018000052A (enExample)
WO (1) WO2017004567A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202016008300U1 (de) 2015-07-02 2017-07-14 PrimeVax Immuno-Oncology, Inc. Zusammensetzungen zur Kombinationstherapie mit Denguevirus und dendritischen Zellen
US10765727B2 (en) 2015-09-26 2020-09-08 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
EP3541417A4 (en) 2016-11-16 2020-05-27 Primevax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
EP3565567A4 (en) * 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
US12274725B2 (en) 2017-06-12 2025-04-15 Washington University Zika virus strains for treatment of glioma
JP2020527540A (ja) * 2017-06-15 2020-09-10 プライムヴァックス イミュノ−オンコロジー，インク． デングウイルスならびに樹状細胞を用いた癌治療のための組成物および方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1015972A (en) 1905-09-25 1912-01-30 Westinghouse Electric & Mfg Co Electric switch.
US1035755A (en) 1908-07-21 1912-08-13 Glenn S Smith Draftsman's apparatus.
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6602709B1 (en) * 1998-02-20 2003-08-05 The Rockefeller University Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
US6048686A (en) 1998-05-05 2000-04-11 Randy Kyle Brown Hyperthermia and immunotherapy for cancer
US6524587B1 (en) * 1998-05-05 2003-02-25 Bruce W. Lyday Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
CN1191092C (zh) 1999-03-26 2005-03-02 沃尔特里德军事研究院 多价登革病毒疫苗
US6511667B1 (en) * 1999-03-26 2003-01-28 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-2 virus vaccine
CA2367590A1 (en) * 1999-03-31 2000-10-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
EP1484064A1 (en) 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
CN101006172B (zh) 2004-06-24 2012-09-05 株式会社载体研究所 包含导入了rna病毒的树突状细胞的抗癌剂
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
CN101155914B (zh) * 2005-04-08 2013-03-06 阿戈斯治疗公司 树状细胞组合物和方法
AU2007285929B2 (en) 2006-08-15 2013-09-05 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of dengue virus vaccine components
WO2008039974A2 (en) * 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
JP2013522309A (ja) 2010-03-15 2013-06-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 活性化した成熟樹状細胞を調製し保存するシステムおよび方法
PH12013502442A1 (en) 2011-05-26 2018-03-21 Glaxo Smithkline Biologicals Sa Inactivated dengue virus vaccine
EP2543386A1 (en) * 2011-07-05 2013-01-09 Sotio a.s. Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
US9879003B2 (en) 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
EP2858668A1 (en) * 2012-06-10 2015-04-15 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
ES2738582T3 (es) 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
WO2016179475A1 (en) 2015-05-07 2016-11-10 Baylor College Of Medicine Dendritic cell immunotherapy
DE202016008300U1 (de) 2015-07-02 2017-07-14 PrimeVax Immuno-Oncology, Inc. Zusammensetzungen zur Kombinationstherapie mit Denguevirus und dendritischen Zellen
US10765727B2 (en) 2015-09-26 2020-09-08 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
EP3541417A4 (en) 2016-11-16 2020-05-27 Primevax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
JP2020527540A (ja) 2017-06-15 2020-09-10 プライムヴァックス イミュノ−オンコロジー，インク． デングウイルスならびに樹状細胞を用いた癌治療のための組成物および方法

Similar Documents

Publication Publication Date Title
JP2018522880A5 (enExample)
Tfouni et al. Biological activity of ruthenium nitrosyl complexes
JP2016531927A5 (enExample)
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
WO2015193359A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
MX2016014711A (es) Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma).
JP2013177430A5 (enExample)
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
GB0700058D0 (en) Anti-tumor vaccine based on normal cells
MX363819B (es) Uniones a cdim y sus usos.
NZ711946A (en) Newcastle disease viruses and uses thereof
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
MX376066B (es) Anticuerpos dirigidos contra cd127.
BR112013031084A2 (pt) meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
RU2014117707A (ru) Способ лечения пролиферативного заболевания
CN104245736A (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
MX2021003826A (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
MX385304B (es) Nuevos complejos metálicos de nocardamina y su uso en composiciones farmacéuticas.
NZ780840A (en) Chiral indole compounds and their use
WO2017041092A3 (en) Anti-survivin antibodies for cancer therapy
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии